AVIR Atea Pharmaceuticals, Inc.

Nasdaq Pharmaceutical Preparations MA CIK: 0001593899
AI RATING
HOLD
62% Confidence

Investment Thesis

Atea demonstrates exceptional revenue growth of 622.5% YoY and maintains a fortress balance sheet with $79.3M cash and 7.89x current ratio, providing substantial financial resilience. However, the company faces critical profitability challenges with operating losses of -$48.0M and negative free cash flow of -$48.3M despite significant revenue scale, raising questions about operational efficiency and business model sustainability.

Strengths

  • + Explosive revenue growth of 622.5% YoY indicates successful commercialization and strong market demand
  • + Fortress balance sheet: 7.89x current ratio, zero debt (0.00x D/E), $79.3M cash position provides ~1.7 years of operational runway
  • + Strong stockholders equity of $233.7M and total assets of $267.1M represent solid capital foundation

Risks

  • ! Significant operating losses (-$48.0M) and negative free cash flow (-$48.3M) despite high revenue, indicating unprofitable growth model
  • ! Negative ROE (-19.4%) and ROA (-17.0%) show the company is destroying shareholder value and not generating returns on assets
  • ! Cash burn rate of $46.4M annually will deplete capital reserves within 1.7 years without achieving profitability or raising additional capital

Key Metrics to Watch

Financial Metrics

Revenue
351.4M
Net Income
-45.4M
EPS (Diluted)
$-0.57
Free Cash Flow
-48.3M
Total Assets
267.1M
Cash
79.3M

Profitability Ratios

Gross Margin N/A
Operating Margin -13.7%
Net Margin -12.9%
ROE -19.4%
ROA -17.0%
FCF Margin -13.8%

Balance Sheet & Liquidity

Current Ratio
7.89x
Quick Ratio
7.89x
Debt/Equity
0.00x
Debt/Assets
14.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-13T07:51:58.771213 | Data as of: 2026-03-31 | Powered by Claude AI